---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-240603"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2024-10-22T23:59:59+00:00"
generated_at: "2026-05-30T11:42:44.571734+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH

## Summary
- Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.
- Proceeds to fund Phase 2b '702' trial of IkT-001Pro in PAH and for general corporate purposes.
- Appointed four new directors: Roberto Bellini (Independent Chair), Amit Munshi, David Canner, Arvind Kush.
- Resignations of Dr. Paul Grint and Gisele Dion, not due to disagreements; fully vested options paid through Dec 31, 2024.
- IkT-001Pro is oral, potentially disease-modifying imatinib prodrug aiming to improve safety/tolerability in PAH.

## SEC filing metadata
- accession: 0001193125-24-240603
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2024-10-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/d902445d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-240603
- JSON: https://secwatch.observer/filing/0001193125-24-240603.json
- Plain text: https://secwatch.observer/filing/0001193125-24-240603.txt

## Key facts
- Executive change
  Roberto Bellini was appointed as Class I director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class I director
  source text: the Board appointed Roberto Bellini to serve as a Class I director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- Executive change
  Roberto Bellini was elected as Independent Chairperson of the Board at Inhibikase Therapeutics, Inc..
  - Action: elected
  - Role: Independent Chairperson of the Board
  source text: The Board has elected Mr. Bellini as independent Chairperson of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- Executive change
  Arvind Kush was appointed as Class III director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class III director
  source text: Arvind Kush to serve as a Class III director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- Executive change
  Paul Grint resigned as director at Inhibikase Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- Executive change
  David Canner was appointed as Class II director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: Amit Munshi and David Canner to serve as Class II directors of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- Executive change
  Gisele Dion resigned as director at Inhibikase Therapeutics, Inc..
  - Action: resigned
  - Role: director
  source text: Dr. Paul Grint and Ms. Gisele Dion (the " Resigning Directors ") became effective as of the effectiveness of the appointment of their respective successors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm
- Executive change
  Amit Munshi was appointed as Class II director at Inhibikase Therapeutics, Inc..
  - Action: appointed
  - Role: Class II director
  source text: Amit Munshi and David Canner to serve as Class II directors of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.